SAVE THE DATE FOR OUR 2019 ANNUAL PUBLIC FORUM ON SEPTEMBER 5, 2019 IN WASHINGTON, DC!
An Early Feasibility Study (EFS) is a small clinical study designed to gain early insights into an innovative medical technology during the development process, before starting a larger clinical trial. An EFS often serves as a critical step in device innovation.
Although conducting an EFS is optional, EFS handle facilitates direct and interactive collaboration between FDA, sponsors and innovators in the earliest product lifecycle stages. Benefits of EFS include first-in-world access to potentially beneficial medical devices to patients in the US. They also familiarize regulatory review teams and care providers with the technology earlier in the product development process, applying a learn-as-you-go approach.
EFS provide the ability to justify doing the right testing at the right time and promote a more streamlined Clinical Testing (see details in Appendix). Capturing EFS data that is relevant to the US population and therefore directly supportive of subsequent US clinical studies (e.g. Pivotal, Post-Market, etc.)
Historically, feasibility studies have often been conducted Outside of the United States (OUS) due to real or perceived resource constraints/requirements (costs and time) associated with US study conduct. When medical technology developers prioritize conducting OUS feasibility and pivotal clinical studies over US studies, the relevant technologies are delayed in reaching US patients, and delayed in providing clinicians with hands-on experience using the technology.
MDIC’s work within the EFS program includes tracking EFS performance metrics, and developing tools and best practices for EFS sponsors and clinical researchers alike. In combination, these efforts are anticipated to drive overall EFS efficiency and support continuous assessment of EFS efficiency and effectiveness for US patients.
The FDA’s Center for Devices and Radiological Health (CDRH) established the EFS program in an effort towards achieving its strategic priority of facilitating First-in-World patient access to safe and effective new technologies of significant health importance. Additionally supporting this priority, the Agency released its final Guidance (October 2013) titled Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies.
Understanding that support during the earliest phases of medical device testing encourages medical device innovation and access for U.S. patients, MDIC, supports this CDRH strategic priority through the Early Feasibility Study (EFS) Working Group. MDIC is in a unique position to develop tools and best practices to support implementation and broad participation of CDRH’s EFS program via close collaboration between FDA, industry, providers and other stakeholders.